137 related articles for article (PubMed ID: 25295906)
41. Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation.
Chisholm JA; Williams G; Spence E; Parks S; Keating D; Gavin M; Mills PR
Aliment Pharmacol Ther; 2005 Mar; 21(6):723-32. PubMed ID: 15771758
[TBL] [Abstract][Full Text] [Related]
42. [Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
Kupś-Rzepecka J; Woźniakowska-Gesicka T; Gołabek V
Przegl Lek; 2011; 68(6):311-5. PubMed ID: 22039668
[TBL] [Abstract][Full Text] [Related]
43. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
[TBL] [Abstract][Full Text] [Related]
44. Combined etiology for bilateral and simultaneous optic neuropathy in a patient with ciancobalamin deficit and hepatitis C treated with peg-interferon and ribavirin.
Pantalon AD; Danielescu C; Chiseliță D
Rom J Ophthalmol; 2016; 60(3):188-194. PubMed ID: 29450347
[TBL] [Abstract][Full Text] [Related]
45. Anterior ischemic optic neuropathy complicating interferon alpha and ribavirin therapy in patients with chronic hepatitisC.
Kabbaj N; Sentissi S; Mohammadi M; Benaïssa A; Amrani N
Gastroenterol Clin Biol; 2009 Feb; 33(2):115-7. PubMed ID: 19201118
[TBL] [Abstract][Full Text] [Related]
46. [Interferon-related retinopathy in a man with chronic hepatitis C].
Viennet A; Glatre F; Bacin F
J Fr Ophtalmol; 2009 Sep; 32(7):505-10. PubMed ID: 19592135
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
[TBL] [Abstract][Full Text] [Related]
48. Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C.
Wang LJ; Chen SW; Chen CK; Yen CL; Chang JJ; Lee TS; Liu CJ; Chen LW; Chien RN
BMC Psychiatry; 2016 Nov; 16(1):424. PubMed ID: 27884134
[TBL] [Abstract][Full Text] [Related]
49. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents.
Al Ali J; Owayed S; Al-Qabandi W; Husain K; Hasan F
Ann Hepatol; 2010; 9(2):156-60. PubMed ID: 20526008
[TBL] [Abstract][Full Text] [Related]
50. Branch retinal vein thrombosis and visual loss probably associated with pegylated interferon therapy of chronic hepatitis C.
Goncalves LL; Farias AQ; Gonçalves PL; D'Amico EA; Carrilho FJ
World J Gastroenterol; 2006 Jul; 12(28):4602-3. PubMed ID: 16874884
[TBL] [Abstract][Full Text] [Related]
51. Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C.
Condat B; Asselah T; Zanditenas D; Estampes B; Cohen A; O'Toole D; Bonnet J; Ngo Y; Marcellin P; Blazquez M
Eur J Gastroenterol Hepatol; 2006 Mar; 18(3):287-9. PubMed ID: 16462543
[TBL] [Abstract][Full Text] [Related]
52. Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Nishiofuku M; Tsujimoto T; Matsumura Y; Toyohara M; Yoshiji H; Yamao J; Fukui H; Yoshikawa M
Intern Med; 2006; 45(7):483-4. PubMed ID: 16679707
[No Abstract] [Full Text] [Related]
53. Pegylated interferon-associated retinopathy in chronic hepatitis C patients.
Ogata H; Suzuki H; Shimizu K; Ishikawa H; Izumi N; Kurosaki M
Jpn J Ophthalmol; 2006; 50(3):293-5. PubMed ID: 16767392
[No Abstract] [Full Text] [Related]
54. Peginterferon/ribavirin treatment achieves a higher compliance rate than interferon/ribavirin combination in patients chronically infected with HCV on methadone maintenance.
Dimitroulopoulos D; Petroulaki E; Manolakopoulos S; Anagnostou O; Tsaklakidou D; Xinopoulos D; Tsamakidis K; Tzourmakliotis D; Paraskevas E
Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1407-12. PubMed ID: 19916203
[TBL] [Abstract][Full Text] [Related]
55. [Sarcoïdose in patient with chronic hepatitis C treated with pegylated interferon].
Moudden MK; Ziadi T; Al Bouzidi A; Ouarssani A; Hadri L; El Baaj M
Rev Pneumol Clin; 2014 Dec; 70(6):362-5. PubMed ID: 25131364
[TBL] [Abstract][Full Text] [Related]
56. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
Slim J; Afridi MS
Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
[TBL] [Abstract][Full Text] [Related]
57. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Hayashi M; Kataoka Y; Tachikawa K; Koguchi H; Tanaka H
Diabetes Res Clin Pract; 2009 Nov; 86(2):e19-21. PubMed ID: 19744739
[TBL] [Abstract][Full Text] [Related]
58. Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C.
Zandieh I; Adenwalla M; Cheong-Lee C; Ma PE; Yoshida EM
World J Gastroenterol; 2006 Aug; 12(30):4908-10. PubMed ID: 16937480
[TBL] [Abstract][Full Text] [Related]
59. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
60. Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin.
Lin J; Lott JP; Amorosa VK; Kovarik CL
J Am Acad Dermatol; 2009 May; 60(5):882-3. PubMed ID: 19389538
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
